Expect 'High Tide' of Chinese Biotech Deals as Threat of US Curbs Fades: Analysts The specter of US curbs has long hung over Chinese biotechnology companies, casting uncertainty over their partnerships and collaborations with American firms.
However, analysts say that threat is finally receding, paving the way for a "high tide" of deals between China and the US.
A Shift in Washington's Approach Changes in the US Treasury Department's draft investment rules are significant.